Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riluzole in Mild Alzheimer's Disease
NCT01703117Phase 2Completed
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Nov 2013
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of riluzole in Alzheimer's disease (AD), sponsored by Icahn School of Medicine at Mount Sinai. Started Nov 2013; status: completed.
02
Drugs
riluzole
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01703117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01703117.